Targeted drugs in oncology: New names, new mechanisms, new paradigm

American Journal of Health-System Pharmacy

Volumn 60, Issue 12, 2003, Pages 1233-1245

  Rotea Jr , William ^a,c   Saad, Everardo D ^b  

^a Department of Medical Oncology   (Brazil)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^c NONE   (Brazil)

Author keywords

Antibodies; Antineoplastic agents; Mechanism of action; Neoplasms; Site of action; Toxicity

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ALEMTUZUMAB; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CANERTINIB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMATINIB; IRINOTECAN; L 778123; LAPATINIB; LONAFARNIB; MITOXANTRONE; MONOCLONAL ANTIBODY; PACLITAXEL; PHOSPHOTRANSFERASE; PREDNISONE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SEMAXANIB; TIPIFARNIB; TOSITUMOMAB; TRASTUZUMAB; UNINDEXED DRUG; VATALANIB; VINCRISTINE; TRANSFERASE;

ADULT RESPIRATORY DISTRESS SYNDROME; ASTHENIA; BACTERIAL INFECTION; BONE MARROW TOXICITY; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EDEMA; ENZYME INHIBITION; FEVER; HEADACHE; HUMAN; HYPOTENSION; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; ONCOLOGY; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; VEIN OCCLUSION; VIRUS INFECTION; WEIGHT GAIN; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; DRUG ANTAGONISM; NEOPLASM; PATHOPHYSIOLOGY;

ALKYL AND ARYL TRANSFERASES; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PROTEIN-TYROSINE KINASES;

EID: 16544390772     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.12.1233     Document Type: Review

References (121)

1. Putnam DA. Antisense strategies and therapeutic applications. Am J Health-Syst Pharm. 1996; 53:151-60.
2. Zwiebel JA. Cancer gene and oncolytic virus therapy. Semin Oncol. 2001; 28: 336-43.
3. Watkins SJ, Norbury CJ. Translation initiation and its deregulation during tumorigenesis. Br J Cancer. 2002; 86: 1023-7.
4. Ponder BA. Cancer genetics. Nature. 2001; 411:336-41.
5. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001; 411:366-74.
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100:57-70.
7. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol. 2001; 19(18, suppl):32S-40S.
8. Laurent E, Talpaz M, Kantarjian H et al. The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res. 2001; 61:2343-55.
9. Barbacid M. Ras genes. Annu Rev Biochem. 1987; 56:779-827.
10. Aaronson SA. Growth factors and cancer. Science. 1991; 254:1146-53.
11. Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Ann Rev Biochem. 1993; 62:453-81.
12. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000; 103:211-25.
13. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001; 411:355-65.
14. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256:495-7.
15. Dillman RO. Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest. 2001; 19:833-41.
16. Maeda T, Yamada Y, Tawara M et al. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. Int J Hematol. 2001; 74:70-5.
17. Ritter G, Cohen LS, Williams C Jr et al. Serological analysis of human antihuman antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res. 2001; 61:6851-9.
18. Wood AM. Rituximab: an innovative therapy for non-Hodgkin's lymphoma. Am J Health-Syst Pharm. 2001; 58:215-29.
19. Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al. IDEC-C2B8: results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997; 15:3266-74.
20. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16:2825-33.
21. Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J Clin Oncol. 2000; 18:3135-43.
22. Hainsworth JD, Burris HA III, Morrissey LH et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000; 95:3052-6.
23. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood. 1998; 92:1927-32.
24. O'Brien SM, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001; 19:2165-70.
25. Dimopoulos MA, Zervas C, Zomas A et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol. 2002; 20:2327-33.
26. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346:235-42.
27. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002; 99:3554-61.
28. Bross PF, Beitz J, Chen G et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001; 7:1490-6.
29. Sievers EL, Larson RA, Stadtmauer EA et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001; 19:3244-54.
30. Lang K, Menzin J, Earle CC et al. Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia. Am J Health-Syst Pharm. 2002; 59:941-8.
31. Witzig TE. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2001; 48(suppl 1):S91-5.
32. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002; 20:2453-63.
33. Kaminski MS, Zelenetz AD, Press OW et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001; 19:3918-28.
34. Press OW, Eary JF, Gooley T et al. A Phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000; 96:2934-42.
35. Pauletti G, Dandekar S, Rong H et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000; 18:3651-64.
36. Treish I, Schwartz R, Lindley C. Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health-Syst Pharm. 2000; 57:2063-76.
37. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999; 17:2639-48.
38. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20:719-26.
39. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344:783-92.
40. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002; 20:1215-21.
41. Crone SA, Zhao YY, Fan L et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002; 8:459-65.
42. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer. 2001; 8:3-9.
43. Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000; 18:904-14.
44. Robert F, Ezekiel MP, Spencer SA et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001; 19:3234-43.
45. Saltz L, Rubin M, Hochster H et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Paper presented at American Society of Clinical Oncology Annual Meeting. San Francisco, CA; 2001 May 12-15.
46. Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 2002; 1:117-23.
47. Iwata KK, Provoncha K, Gibson N. Inhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva). Paper presented at American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2002 May 18-21.
48. Raben D, Helfrich BA, Chan D et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002; 29(1, suppl 4):37-46.
49. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561-6.
50. Heinrich MC, Griffith DJ, Druker BJ et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000; 96: 925-32.
51. Buchdunger E, Zimmermann J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996; 56:100-4.
52. Kantarjian H, Sawyers C, Hochhaus A et al. The International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346:645-52.
53. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344:1038-42.
54. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Eng J Med. 2003; 348:994-1004.
55. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998; 11:728-34.
56. Rubin BP, Singer S, Tsao C et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001; 61:8118-21.
57. Heinrich MC, Corless CL, Blanke C et al. KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Paper presented at American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2002 May 18-21.
58. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472-80.
59. Van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet. 2001; 358:1421-3.
60. Baselga J, Herbst R, LoRusso P et al. Continuous administration of ZD 1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability. Paper presented at American Society of Clinical Oncology Annual Meeting. New Orleans, LA; 2000 May 20-23.
61. Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001; 19:3267-79.
62. Kris MG, Natale RB, Herbst RS et al. A Phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Paper presented at American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2002 May 18-21.
63. Fukuoka M, Yano S, Giaccone G et al. Final results from a Phase II trial of ZD1839 ('Iressa') for patients with advanced non-small cell lung cancer (IDEAL 1). Paper presented at American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2002 May 18-21.
64. Natale RB, Skarin A, Maddox A-M et al. Improvement in symptoms and quality of life for advanced non-small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Paper presented at American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2002 May 18-21.
65. Douillard J-Y, Giaccone G, Horai T et al. Improvement in disease-related symptoms and quality of life in patients with advanced non-small cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1). Paper presented at American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2002 May 18-21.
66. Cohen EEW, Rosen F, Dekker A et al. Phase II study of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paper presented at American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2002 May 18-21.
67. Senzer NN, Soulieres D, Siu L et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Paper presented at American Society of Clinical Oncology Annual Meeting. San Francisco, CA; 2001 May 12-15.
68. Slichenmyer WJ, Elliott WL, Fry DW. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol. 2001; 28(5, suppl 16):80-5.
69. Reinhart JJ, Wilding G, Willson J et al. A Phase I clinical and pharmacokinetic study of CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Paper presented at American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2002 May 18-21.
70. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1:27-31.
71. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001; 93:178-93.
72. Fox SB, Harris AL. Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. Invest New Drugs. 1997; 15:15-28.
73. Neufeld G, Cohen T, Gengrinovitch S et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999; 13:9-22.
74. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001; 19:843-50.
75. Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001; 19:851-6.
76. DeVore RF, Fehrenbacher L, Herbst RS et al. A randomized Phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Paper presented at American Society of Clinical Oncology Annual Meeting. New Orleans, LA; 2000 May 20-23.
77. Bergsland E, Hurwitz H, Fehrenbacher L et al. A randomized Phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Paper presented at American Society of Clinical Oncology Annual Meeting. New Orleans, LA; 2000 May 20-23.
78. Yang JC, Haworth L, Steinberg SM et al. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Paper presented at American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2002 May 18-21.
79. Brahmer JR, Kelsey S, Scigalla P et al. A Phase I study of SU6668 in patients with refractory solid tumors. Paper presented at American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2002 May 18-21.
80. Yung WA, Friedman H, Jackson E et al. A Phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGFR TK inhibitor in recurrent glioblastoma. Paper presented at American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2002 May 18-21.
81. Rosen L, Mulay M, Mayers A et al. Phase 1 dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Paper presented at American Society of Clinical Oncology Annual Meeting. Atlanta, GA; 2000 May 15-18.
82. Kuenen BC, Rosen L, Smit EF et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol. 2002; 20:1657-67.
83. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer. 2000; 7:165-97.
84. United States Food and Drug Administration Center for Drug Evaluation and Research. Thalidomide information. www.fda.gov/cder/news/thalinfo/default.htm (accessed 2002 Apr 26).
85. D'Amato RJ, Loughnan MS, Flynn E et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994; 91:4082-5.
86. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999; 341:1565-71.
87. Little RF, Wyvill KM, Pluda JM et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000; 18: 2593-602.
88. Fine HA, Figg WD, Jaeckle K et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000; 18: 708-15.
89. Stebbing J, Benson C, Eisen T et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer. 2001; 85:953-8.
90. Figg WD, Dahut W, Duray P et al. A randomized Phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 2001; 7: 1888-93.
91. Baidas SM, Winer EP, Fleming GF et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol. 2000; 18:2710-7.
92. Tseng JE, Glisson BS, Khuri FR et al. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2001; 92:2364-73.
93. Raza A, Meyer P, Dutt D et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001; 98:958-65.
94. Steins MB, Padro T, Bieker R et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood. 2002; 99:834-9.
95. Stirling D. Thalidomide: a novel template for anticancer drugs. Semin Oncol. 2001; 28:602-6.
96. Wojtowicz-Praga S, Torri J, Johnson M et al. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol. 1998; 16:2150-6.
97. Bramhall SR, Rosemurgy A, Brown PD et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol. 2001; 19:3447-55.
98. Groves MD, Puduvalli VK, Hess KR et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol. 2002; 20:1383-8.
99. Bissett D, O'Byrne KJ, von Pawel J et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small cell lung cancer (NSCLC). Paper presented at American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2002 May 18-21.
100. Levin V, Phuphanich S, Glantz MJ et al. Randomized Phase II study of temozolomide (TMZ) with and without the matrix metalloprotease (MMP) inhibitor prinomastat in patients (pts) with glioblastoma multiforme (GBM) following best surgery and radiation therapy. Paper presented at American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2002 May 18-21.
101. Hess KR, Abbruzzese JL. Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. J Clin Oncol. 2001; 19:3445-6. Editorial.
102. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 1999; 17:3631-52.
103. Zujewski J, Horak ID, Bol CJ et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2000; 18: 927-41.
104. Karp JE, Lancet JE, Kaufmann SH et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a Phase 1 clinical-laboratory correlative trial. Blood. 2001; 97:3361-9.
105. Adjei AA, Erlichman C, Davis JN et al. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 2000; 60:1871-7.
106. Eskens FA, Awada A, Cutler DL et al. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol. 2001; 19:1167-75.
107. Britten CD, Rowinsky EK, Soignet S et al. A Phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin Cancer Res. 2001; 7: 3894-903.
108. Cloughesy TF, Kuhn J, Wen P et al. Phase II trial of R115777 (Zarnestra) in patients with recurrent glioma not taking enzyme inducing antiepileptic drugs (EIAED): a North American Brain Tumor Consortium (NABTC) report. Paper presented at American Society of Clinical Oncology Annual Meeting. Orlando, FL; 2002 May 18-21.
109. Kurzrock R, Wilson EF, Sebti SM. Clinical activity and inhibition of protein farnesylation in FTI-R115777 treated patients with myelodysplastic syndrome (MDS). Paper presented at American Association for Cancer Research Annual Meeting. San Francisco, CA; 2002 Apr 6-10.
110. Geels P, Eisenhauer E, Bezjak A et al. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol. 2001; 19:3267-79.
111. Rothenberg ML, Abbruzzese JL, Moore M et al. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer. 1996; 78 (3, suppl):627-32.
112. Howell A, Mackintosh J, Jones M et al. The definition of the "no change" category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol. 1988; 24:1567-72.
113. Blum JL, Jones SE, Buzdar AU et al. Multicenter Phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999; 17:485-93.
114. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92:205-16.
115. Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a Phase I trial. J Clin Oncol. 2002; 20:2240-50.
116. Kabbinavar FF, Johnson D, Langmuir VK et al. Patterns of tumor progression during therapy with bevacizumab (BV) and chemotherapy (CT) for metastatic colorectal cancer (CRC) and advanced non-small cell lung cancer (NSCLC). Paper presented at American Society of Clinical Oncology Annual Meeting. San Francisco, CA; 2001 May 12-15.
117. Stadler WM, Ratain MJ. Development of target-based antineoplastic agents. Invest New Drugs. 2000; 18:7-16.
118. Albanell J, Rojo F, Averbuch S et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002; 20:110-24.
119. Libutti SK, Choyke P, Carrasquillo JA et al. Monitoring responses to antiangiogenic agents using noninvasive imaging tests. Cancer J Sci Am. 1999; 5:252-6.
120. Dent S, Zee B, Dancey J et al. Application of a new multinomial Phase II stopping rule using response and early progression. J Clin Oncol. 2001; 19:785-91.
121. Hellman S. The first century of cancer chemotherapy. J Clin Oncol. 1998; 16: 2295-6. Editorial.